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Conference “Dose, Time and Fractionation” is recognized
worldwide, with a long tradition of over 28 years. It is
always organized in Madison, Wisconsin in the US. The
number of participants and invited speakers is rather
restricted yet every four years it is an important event in
the itinerary of radiotherapy meetings. The important
advantage of this conference is that it is always aimed at
presenting what has been done in the past four years and
what are the new and the most promising developments
which should be challenged in the next four years. Over
the last decade there have been significant technological,
physical, molecular and biochemical developments in
radiation oncology that have created a tremendous
potential for dose escalation in the delivery of radiation
treatment. New tools allow higher confidence in tumour
targeting and normal tissue sparing by providing
conformal dose distribution. This allows to shift the dose
distribution to the surface of the target volume with
a rapid “fall off” in the normal tissues. While the previous
6th Conference concentrated on altered fractionation and
treatment outcomes, the present 7th Conference has
focused on precision of target delineation, static 3D- and
dynamic 4D- imaging and molecular guided dose painting
and molecular modulation.
According to Bentzen we are progressively moving
toward t h e r a g n o s t i c  r a d i o t h e r a p y (i.e. with
knowledge how to treat) which refers to biological
information at the level of the individual patient which
allows selecting a specific therapy and improving the
therapeutic outcome in each individual case – relative to
the outcome after standard therapy.
Tumour imaging and target delineation
Evolution from static (diagnostic and planning) toward
dynamic imaging (treatment monitoring) became crucial
for the precision of planning and dose delivery, especially
for 3D-4D conformal and IMRT radiotherapy. Haslam
from Chicago has shown that static treatment plan
evaluation using single dose volume histograms only may
not be representative for the dose delivered to the
selected structures and may lead to underdosing the
clinical target volume (CTV), or overdosing the organs of
risk (OARs). Gregoire from Brussels has shown extensive
studies on delineation errors of the primary tumour GTV,
and large variations in definition of CTV1, and CTV2 due
to unprecise interpretation of static CT images. New
imaging modalities, such as dynamic enhanced DCE
NMR (presented by Ling form Sloan Kettering CC, New
York), FDG-PET, 18F-MISO PET, and 3’-deoxy-fluoro-
thymidine FLT-PET (Jeraj from Madison) together with
image-fusion allow to increase the precision of tumour
and organ-at-risk delineation, and provide functional
images of tumour hypoxia and tumour repopulation
intensity. According to Ling, FLT-PET images can be
considered as a surrogate for tumour proliferation.
Increases in FLT indicate early accelerated repopulation
whereas significant decreases in FLT strongly correlated
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with tumour-cell clearance. Metcalfe from Australia
presented a dynamic program of Beam-Eye-Views
(BEVs) which allows to validate radiotherapy planning
dose prediction for IMRT technology.
Although tomotherapy (IMRT combined with CT
on time and on line) has been known since the late
nineties, mainly in Madison, a few new centres have
recently been developed in the US and in Canada.
Kupelian from Orlando has presented an elegant
technique of IMRT/tomotherapy for prostate cancer. In-
room, cone-beam CVCT imaging is adapted to the
TomoTherapy HiArt II helical accelerator to perform
highly adaptive radiation therapy. A motorized couch
driven by an on-board computer makes inverse treatment
planning possible with different pitch ratios, jaw widths,
and modulation factor and thus it is possible to use an
optimal plan for a specific treatment site. CT images with
a delivered dose of 1-3 cGy per scan are generated prior
to each treatment and fused with original planning CT
images to reposition patients to the simulated and
planning positions. Daily evaluation of dose, including
dosimetric variations in target and normal tissues, leads to
image- and dose-guided radiotherapy.
Apart from uncertainties in the delineation of the
GTV, CTV1, CTV2 volumes, organ motions become one
of the most important aspects of precision in radio-
therapy. Organ motion due to physiological functions can
be substantial. For example, the liver can move up to five
centimeters in the caudal-cranial direction during free
breathing, causing motion of the entire upper abdominal
and lower thoracic cavity. Organ motion due to cardiac
function, gastrointestinal peristalsis, stomach filling, rectal
filling, bladder filling and swallowing can also occur
during therapy. Furthermore, patients may involuntarily
change their position during the treatment session, due to
discomfort or session prolongation.
Dawson from PMH in Toronto has focused on
strategies to compensate for breathing motion, including
voluntary shallow breathing, deep inspiration, breath
holds at variable phases of the respiratory cycle, gated
radiotherapy and real-time tumour tracking. Among the
many techniques gated radiotherapy with the beam
triggered only at the same phase of the respiratory cycle
appears to be the most efficient. The real-time tracking
system consisting of fluoroscopic x-ray tubes in the
treatment rooms and allows visualization of radio-opaque
markers. The linear accelerator is triggered to irradiate
only when the marker is located within the planned
treatment region. As the tumour shifts outside the
treatment region the multileaf collimators, the couch
position or the entire accelerator may move with it
tumour to ensure adequate tumour coverage at all times.
The diagram on Figure 1 shows step-by-step procedures
starting with the collecting of topographic and functional
images for 3D-contouring of the defined targets. 3D-
planning is based on a series of DVHs to optimize the
treatment plan. The simplest solution is that the radiation
beam is delivered only during the same phase of the
respiratory cycle. The conceptof this method resembles
that behind tomotherapy and pulsed brachytherapy.
To summarize, at presernt it is obvious that the use
of the DVHs based on unfrequent series of CT images or
even the use of the MLC does not automatically render
planning and dose delivery conformal. During the
Conference it has been clearly pointed out that the name
“conformal” is often overused. High-tech accelerators
and other tools are tools only and do not automatically
legitimate conformity. Knowledge and experience are
also important, and probably even more so. Therefore,
sometimes conformal radiotherapy is onl;y the term used,
and in fact not performed. The criteria for conformal
radiotherapy recommended during the conference are
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Figure 1. Step-by-step diagram of 4D-gating radiotherapy
presented in Table I. However, one has to bear in mind
that step-by-step procedures of 3D-conformal and IMRT
radiotherapy can be the source of numerous uncertainties,
including delineation errors, margin errors due to the
presence of microscopic disease and set-up errors, which
may significantly decrease the estimated probability
of tumour control. Even very small and physical cold
spots within the CTVs may overrule all advantages of the
method. On the other hand, organ motion becomes
a critical issue when all procedures are precisely and
properly performed. P r e c i s e  i n a c c u r a c y might be
the potential risk of high-tech radiotherapy. It may explain
why there is an urgent need to replace static images by
dynamic images, CT-NMR-PET fusions, functional
images of tumour hypoxia, proliferation including
molecular tumour profile to improve tumour and normal
tissue contouring, organ stability defining and tumour
heterogeneity, and all of them can be an important step
forward to increase therapeutic gain in radiotherapy.
Moreover, Bentzen, Niemierko and Withers have clearly
documented, that in order to take full advantage of
technological and imaging capabilities an improved
biological knowledgebase is required. For 3D and 4D
conformal, IMRT irradiation, single and static DVHs
providing physical dose-volume relationships may often
be misleading while the radiation-bioeffect estimates
based on linear-quadratic model, which in turn can help
to define how far dose-fractionation can be utilized may
be necessary.
Optimizing dose fractionation
Assuming that treatment planning and radiation delivery
is highly precise, all possible technical and physical
dosimetric errors can be minimized by daily monitoring
using interfraction dynamic CT (PET) imaging. It allows
to correct deviations between the actually delivered and
the prescribed dose. With tumour (node) regression
during treatment it has to be remembered that the
primary topography of the tumour and organs at risk
usually changes, in some cases even significantly, thus
calling for resimulation and replanning due to which the
delivery is reoptimized, and thus throughout the entire
treatment course the dose can be maintained as closely as
possible to that originally planned. The so-called daily
image guidance has already been introduced into daily
practice in some centres. This process is referred to as
“generalized adaptive radiotherapy”. The idea is that the
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Table I. Criteria for 3D-Conformal (IMRT) radiotherapy recommended at present
Procedures and steps Who should do it?
WHO and WHAT?
(qualification)
Tumours close to critical normal organs (OARs) the tolerance of which is much lower that the predicted TCD RO
Tumour contours relatively well defined with predictable microscopic spread RO
Tumours with moderate or low radiosensitivity, with heterogeneous cell density, and/or with present or deducable 
hypoxia sublesions RO
Mainly tumours with an average and lower local control probability (TCP ≤50%)
WHEN?
Sole treatment with dose escalation intent (SIB) RO
Pre- or postoperative (with uncertain margins close to OARs) RO, S
As a boost after conventional techniques RO
Combined with concurrent chemotherapy RO, MO
HOW?
3D-CT frequent images (~every 5 mm) RO, RD
3D-targest reconstructions RO, RD
GTV, CTV1.... CTVn, PTV delineations RO (PH)
3D simulation with BEV RTT, RO
3D treatment planning with at least a few DVHs and BN-DVHs (to make optimal choice) RO, PH
Interpretation of OAR constraints and dose-volume distribution for OARs on BN-DVHs beyond 
the constraints (critical!) RO
Choice of optimal solution RO
Patient immobilization, and set-up at the first session, PVI, Exac-Track, dosimetry in vivo RTT, PH, RO
Every session PVI monitoring (come-beam CT) RTT
Standard dosimetry in vivo after delivery of a half of the planned dose or after pronounced tumours regression PH
Resimulation repositoning, replanning if needed RO, PH, RTT
Legend TCD – Tumours Cure Dose, OAR – organ(s) at risk, SIB – Simultaneous Infield Boost, BEV – Beam-Eye-View, BN-DVH – Biologically
Normalized Dose Volume Histogram, PVI – Portal Vision Imaging, RO – radiation oncologist, S – surgeon, MO – medical oncologist, PH –
medical physicist, RTT – radiation technologist
tumour and organs at risk receive the doses which have
been planned to be delivered. Therefore the unrepaired
DNA damage can be modulated in space and time. These
concepts, and their practical application, have been clearly
illustrated by a few speakers, mainly by Mackie from
Madison, USA, Metcalfe from Wollongong in Australia,
and by Altman from Chicago.
When optimal technical and physical precision is
achieved, dose fractionation becomes the major attribute
of therapeutic benefit. K. Ang from MDACC in Houston
has presented an elegant review of the results of many
clinical trials on altered radiotherapy recommending some
of them as a standard regimens (Table II) Bentzen has
postulated that if the boost dose is needed, it should be at
least 14 Gy, although according to the available clinical
data a dose close to 21 Gy is preferred. It is important
to remember, that the boost should be delivered as fast
as possible. Continuing this topic Withers and Lee
have clearly demonstrated that the beneficial effect of
the boost strongly depends on local tumour control
probability (LTCP) predicted prior to the treatment, and
on the boost volume. The greatest benefit can be expected
only when pretreatment LTCP is moderate (≤50%) and if
the boost volume is similar to the primary GTV. Therefore
there is no reason to boost through a very small field or in
early stages of cancer when the LTCP is already high
(≥80%).
Maciejewski presented long-term results of 7-day
regimen (CAIR-I) showing that 6-year LTC and disease-
free survival keep higher by 35% comparing with
conventional standard 5-day regimen. By decreasing the
dose per fraction one develops the 7-day regimen, which
is undoubtedly safe and acute mucosal reactions, although
severe, are found tolerable by patients. However the
question whether 7 fractions in 7 day (weekend-in) is
similar or more effective tthan 7 fractions in 5 days
(weekend-off concomitant boost) still remains open
because the CAIR-II trial dedicated to this issue is
still ongoing. On the other hand, CAIR-I and CAIR-II
have provided important observations concerning
acute mucosal reactions. First of all, the five-grade
EORTC/RTOG scale has been shown not to be precise
enough to score the severity of acute mucositis, because
grade 4 severity varies significantly among individual
patients, and all, more or less serious, functional and
subjective problems occur above grade 4 although they
are all accounted for within this very grade. Therefore
the Dische system is much more suitable for scoring and
recording acute mucosal reactions. Second, the frequency
of taking the score is crucial to render a precise and true
to life pattern of acute effects. Interim results of CAIR-II
have shown that the severity of acute confluent mucositis
is w a v e - l i k e and could be quantified precisely only
with regular, at least trice-a-week scoring. Irregular or
regular weekly scoring procedures allow to miss a sub-
stantial number of cases of confluent mucositis and their
incidence can be underestimated even by about 30-40%.
Suwiƒski has presented an interim report on
postoperative CAIR for H&N cancers showing a higher
incidence, severity and duration of confluent mucositis
in the study-arm as compared with the conventional
postoperative regimen, but these reactions were well
tolerated by the patients. Miszczyk has shown that
a hyperfractionated accelerated split-course regimen with
64 Gy in 28 days (CHA-CHA) is an effective 4-week
treatment for advanced T3-4 N2-3 head and neck caner
allowing for a 44% 2-year locoregional control. Tarnawski,
by analyzing spectroscopic signals of 1H-MRS in vivo has
demonstrated that postirradiation biochemical changes
in normal brain occur also outside the irradiated volume,
what may suggest that an acute reaction in normal tissue
may not be a local effect restricted to the irradiation
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Table II. Altered fractionation regimens for IMRT more effective than
conventional 66-70 Gy in 2 Gy fractions, recommended by K. K. Ang
General
66-72 Gy in 1.8-2.0 Gy fractions over 6 weeks (twice-a-day for 5-12 days)
or
79,2-81,6 Gy 79.2-81.6 Gy in 1.2 Gy fractions over 7 weeks (twice-a-day during whole therapy
Specific IMRT
for T1-T2
CTV1: 66 Gy in 30 fractions over 6 weeks (dx = 2.2 Gy)
CTV2: 54 Gy in 30 fractions over 6 weeks (dx = 1.8 Gy) [subclinical disease]
for T3-T4
CTV1: 70 Gy in 35 fractions over 6 weeks (dx = 2.0 Gy)
CTV2: 56-59.5 Gy in 35 fractions over 6 weeks (dx = 1.6-1.7 Gy)
[no concurrent chemotherapy is planned]
IMRT with concurrent chemotherapy
CTV1: 70 Gy in 35 fractions over 7 weeks
CTV2: 52.5-56 Gy in 35 fractions over 7 weeks (dx=1.5–1.6 Gy)
volume but it may have generalized biochemical and
functional consequences.
Although the evidence of a low alpha/beta ratio for
prostate cancer is criticized by some authors, Ritter from
Madison has presented the preliminary results of a three-
level hypofractionated trial with fractionation regimens
designed by J. Fowler. The three dose fractionation levels
are: 64.7 Gy in 22 fractions with dx=2.94 Gy, 58.08 Gy in
16 fractions of 3.63 Gy and 51.6 Gy in 12 fractions of 4.3
Gy delivered in three randomized groups of patients with
prostate cancer using image-guided IMRT. Acute rectal
and bladder toxicity were moderate and well tolerated
by patients independently of the dose-fraction delivery
in four or five fractions per week. According to the
Madison group hypofractionation offers the potential for
therapeutic gain and economic and logistic advantage.
To summarize the presentations and discussion on
dose fractionation – clinical practice has gained some
recommendations concerning altered radiotherapy as
a standard procedures (Figure 2), however in the majority
of them the use of IMRT is advocated. Currently the
advances in biology have inspired searches for selective
enhancers of tumour response.
Novel therapeutic approaches using molecular
inhibitors and modifiers
An overview of clinical trials on chemotherapy
administered concurrently with radiotherapy, presented
by Tannock from the PMH in Toronto, provides level 1
evidence of survival benefit for patients with head and
neck, cervix and non-small cell lung cancers and level 2
evidence for brain (or gliomas), eosophagus, rectal and
bladder cancers.
An increase in the therapeutic index has indeed been
noted, however at the expense of an increased toxicity, but
the enhancement of tumour cell kill from chemoradiation
was greater than normal tissue toxicity. Generally
neoadjuvant chemotherapy given prior to radiotherapy
does not improve the treatment outcome or, if npresent,
the benefit is very small. Adjuvant chemotherapy might
likely be effective for some tumours, such as breast
cancer. Cytostatic drugs may sterilize microscopic deposits
of tumour cells while the primary tumour is treated
effectively with surgery and radiotherapy, and therefore
there is no requirement for the interaction of chemo-
therapy with radiotherapy or surgery. Scheduling of the
modalities is not likely to be important. In case of tumour
such as head and neck cancers, where distal failure is
rare, chemotherapy of micrometastases is unlikely to be
a major strategy leading to improved outcome, and long-
term benefit is more likely to be achieved through local
control improvement.
Continuing, Tannock has criticized the concept
chemo-radio sensitization, since the only known process
that might lead to selective radiosensitization is hypoxia,
and the usual cytotoxic drugs are not hypoxic radiation
sensitizers. Cytotoxic drugs activity against rapidly-
proliferating tumour cells is another unlikely possibility,
because the administered doses are generally insufficient
to have a major cell-kill effect against subpopulations of
tumour cells that have survived through radiotherapy and
repopulate fast. Selective toxicity to hypoxic tumour cells
also seems unlikely, because except for tiripazamine,
which has this property, a maaajority of anticancer drugs
are either non-selective or may be more active against
aerobic cells.
Tannock has pointed to the remarkable hetero-
geneity of tumour sensitivity to anti-cancer drugs,
regardless of whether the drug is used to kill cells, to
inhibit proliferation, or for some other goal. For these
reasons, the use of the same drugs with radiation to treat
tumours of the same type in different patients will
inevitably provide limited benefit.
Following molecular (gene-expression) profiling,
molecular inhibitors and modifiers are, currently, one of
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Figure 2. Ranges of dose and time for IMRT for head and neck and prostate cancers recommended 
by 7th Conference “DTF”
the most promising areas for the advancement of
molecular-targeting radiotherapy. According to Harari
from Madison, a series of EGFR inhibitors from both
the monoclonal antibody (mAb) and tyrosine kinase
inhibitor (TKI) class have demonstrated clear clinical
activity. Three EGFR inhibitors including the mAb
cetuximab (Erbitux), small molecule TKIs grefitinib
(Iressa) and erlotimib (Tarceva) have been approved.
A phase III trial for head and neck cancer has shownthat
patients with low EGFR expression have an appro-
ximately 30% better long term prognosis. By combining
EGFR inhibitor-cetuximab with radiation, a 10% increase
in locoregional control and a 9% increase in overall
survival has been documented. Nevertheless, the overall
clinical profits associated with EGFR inhibitors are
modest when analysed in view of the global cancer
population. This suggests that methods of patient
selection should be optimized. On the other hand, the
increasing knowledge on tumour biology provides
convincing evidence that tumour cells use a network of
signaling pathways, and even if one pathway is blocked by
a respective molecular inhibitor, the tumour cells are
flexible enough to use another one to survive and to
continue their life activity.
Harari and Ang have suggested that several signal-
transducation levels should be blocked at the same time,
e.g. simultaneous inhibition of EGFR, other ErbB
receptors as HER-1, HER-3, HER-4 together with
VEGFR pathways, EGFR and COX-2 signaling, P13K
blockade leading to radiosensitization with VEGFR
inhibitors blocking tumour angiogenesis. The use of
angiogenesis inhibitors can normalize tumour vasculature
and improve proliferation and oxygenation. According
to Camphausen from NCI in Bethesda, VEGFR in-
hibitors are clinically promising in the combined
treatment of glioblastoma multiform (GBM). It seems
that the major reason of a poor outcome in patients with
GBM is not tumour cell intrinsic resistance, but rather the
tremendous potential of tumour angiogenesis. The use
of VEGFR inhibitors combined with radiation has
produced promising preliminary clinical results.
The results of a clinical trial presented by Mehta
from Madison utilizing temozolomide with external
radiotherapy over 6 weeks followed by up to 6 cycles of
maintenance of this compound are also interesting.
Temozolomide is an alkylating agent which methylates
DNA. The key lesion is methylation of the 06 position
of guanine which, under normal circumstances is repaired
by the enzyme AGAT. on temozolomide administration
the enzyme is methylated and therefore deactivated,
which makes AGAT a suicide enzyme. Such inactivation
of AGAT results in a significant survival benefit of 48% 2-
year survival, as compared to 14% when the AGAT gene
is active or unmethylated. However, even if the AGAT is
inactivated cytotoxicy is not a universal phenomenon.
Preclinical data suggest that wild type p53 may be
required for inducing apoptotic death. It is not a single
and simple way to eradicate GBM effectively. It is
commonly known that EGFR up-regulation, especially
through the expression of a mutant form of EGFR, is
a frequent event in GBM and may provide a survival
advantage to the tumor. A second critical pathway is the
unopposed activity of P13 kinase through the mutation in
the PTEN gene, which results in the abrogation of
apoptosis in these tumours. Respective inhibitors have
already been combined with radiotherapy for GBM and
the study is still ongoing.
Conclusions
First of all, the Conference has shown the tremendous
progress in radiation techniques and medical physics.
Radiotherapy remains a sole treatment only in a carefully
selected group of tumour sites and stages. The
manufacturers provide us with high-tech tools and
innovations. Static CT and NMR or PET images are
widely replaced by dynamic fusion of CT-NMR-
PETcombined with image monitoring during treatment.
Functional images already allow to define hypoxic and
highly proliferate subregions of the tumours. However,
one should be very naive to think that these high-tech
simulators, accelerators and supportive tools will solve
all problems and they are the warranty of good clinical
practice. These tools are tools only. Evidence-based
criteria for 3D-conformal and IMRT radiotherapy are
well defined and there is no doubt as to the fact that
these techniques are very sophisticated and complicated.
Moreover, organ motion, which was more or less ignored
in the past, has recently become a crucial element of
these procedures. It is important to continue the research
into molecular imaging and treatment guidance, although
these areas are still more in the field of pure science and
are just beginning to have practical application.
The increasing number of the already collected
experimental and clinical data in this field suggest that the
genetic and molecular network of signaling pathways is
complex and may vary individually. They provide clear
evidence that human beings and their malignant tumours
are relentlessly non-linear, i.e. they are highly hetero-
genous. Consequently, all accepted standards are only
averaged guidelines, which should be individually
modified for individual patient application. It is important
that new techniques and treatment strategies are tested
clinically, but they should not be indiscriminately
introduced into daily practice. The road from new
perspectives to new standards is long. It is one of the
important conclusions of the Conference in Madison.
Meanwhile, precision in target imaging, definition and
monitoring, dose and fractionation planning and
prescription, and dosimetry of dose delivery are the major
warrants of effective radiotherapy. Therefore, training,
experience and skills are the basic attributes of good
practice in radiotherapy. A couple of years ago this
had been defined by Fo w l e r  a s  3 P in radiotherapy
(and also in other medical specialities) – P a t i e n t s,
P a t i e n c e  a n d  P r a c t i c e. If one wants to treat
patients, and to cure them, very good performance is
necessary. According to Bentzen, to know whom, when
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and how to treat calls for selecting a specific therapy
based on biological information and this is called
t h e r a g n o s t i c  t h e r a p y.
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